サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1433351

バイオマーカー臨床フェーズアウトソーシングサービスの世界市場（2023年～2030年）

Global Biomarker Clinical Phase Outsourcing Services Market 2023-2030
出版日: | 発行: Orion Market Research | ページ情報: 英文 210 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.70円
バイオマーカー臨床フェーズアウトソーシングサービスの世界市場（2023年～2030年）
出版日: 2023年12月15日
発行: Orion Market Research
ページ情報: 英文 210 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のバイオマーカー臨床フェーズアウトソーシングサービス市場規模、シェア、動向分析レポート：タイプ別（予測バイオマーカー、予後バイオマーカー、安全性バイオマーカー、代替エンドポイント）、治療領域別（腫瘍学、循環器学、神経学、自己免疫疾患）、エンドユーザー別（製薬企業、バイオテクノロジー企業）、予測期間別（2023年～2030年）

バイオマーカー臨床フェーズアウトソーシングサービスの世界市場は、予測期間（2023年～2030年）中にCAGR 21.3％で成長すると予測されます。医薬品開発プロセスの増加や、がん、心血管疾患、神経疾患などの慢性疾患の有病率の上昇などの重要な要因により、早期発見、疾患モニタリング、治療反応評価のためのバイオマーカーへの注目が高まっています。世界保健機関（WHO）は、毎年1,790万人の命を奪っていると推定しています。さらに、米国がん協会によると、2020年には、世界で新たに1,810万人のがん患者が発生し、990万人ががんで死亡すると推定されています。喫煙率の上昇、食習慣の乱れ、運動不足などの要因により、がんの負担は今後増加すると予測されています。バイオマーカーは、様々な健康や病気の特徴を示します。

セグメント別の展望

循環器内科サブセグメントがバイオマーカー臨床フェーズアウトソーシングサービスの世界市場でかなりのシェアを占めると予測される

バイオマーカー臨床フェーズアウトソーシングサービスの世界市場において、治療領域の中でも循環器サブセグメントが大きなシェアを占めると予想されます。このセグメントの成長は、冠動脈疾患、心不全、心臓弁膜症の有病率の増加と、冠動脈臨床試験および技術進歩に対する需要の高まりに起因しています。2023年1月に発表された英国心臓財団（BHF）のデータによると、2021年、最も一般的な心血管疾患には冠動脈（虚血性）心疾患（2019年の世界有病率は2億人と推定）、末梢動脈（血管）疾患（1億1,000万人）、脳卒中（1億人）、心房細動（6,000万人）が含まれると報告されています。さらに、心臓・循環器疾患の有病率は、北米で4,800万人、欧州で1億人、アフリカ・中東で9,800万人、ラテンアメリカで4,800万人、アジア・オーストラリアで3億4,000万人であることが明らかになった。

地域別の展望

バイオマーカー臨床フェーズアウトソーシングサービスの世界市場は、北米（米国、カナダ）、欧州（英国、イタリア、スペイン、ドイツ、フランス、その他欧州地域）、アジア太平洋地域（インド、中国、日本、韓国、その他アジア地域）、世界のその他の地域（中東とアフリカ、中南米）を含む地域別にさらに細分化されます。なかでもアジア太平洋地域は、がん罹患率の増加、インドや中国などの新興経済圏に製造活動をアウトソーシングする欧米製薬企業の増加により、アジア太平洋地域のバイオマーカー臨床フェーズアウトソーシングサービス市場を牽引しており、世界市場で突出したシェアを占めると予想されます。

北米地域は世界のバイオマーカー臨床フェーズアウトソーシングサービス市場において著しいCAGRで成長すると予想されます。

すべての地域の中で、北米は予測期間中にかなりのCAGRで成長すると予想されています。市場成長の背景には、北米全域で心血管疾患が増加していることがあり、今後数年間は臨床試験市場の成長にプラスの影響を与えると推定されます。米国心臓協会（AHA）によると、CVDは依然として米国における主要な死因であり、2020年の死亡者数は928,741人です。米国がん協会（American Cancer Society）は、2023年には米国で新たに190万人以上のがん患者が発生すると推定しています。米国では2023年に約609,820人ががんで死亡すると予想されており、これは1日当たり約1,670人の死亡に相当します。さらに、世界臨床試験、Caidya、ICON plcなど、バイオマーカー臨床フェーズアウトソーシングサービスを専門とする確立された開発業務受託機関が存在します。臨床研究に革新的で画期的な技術が導入され、最先端のインフラが整備されたことで、この地域では心臓疾患の臨床試験が数多く実施されています。Clinicaltrials.govによると、2023年9月現在、米国では約5,068件のバイオマーカー臨床フェーズアウトソーシングサービスが登録されています。

レポート内容

  • 2022年の市場価値データ分析と2030年までの予測
  • 各市場セグメントの年間市場収益
  • 主要地域の国別分析
  • バイオマーカー臨床フェーズアウトソーシングサービスの世界市場で事業を展開する主要企業（データの入手可能性に基づき、新製品発表や関連ニュースに関連する情報も掲載）
  • 今後の力強い成長が見込まれる主要市場セグメントを特定することによる事業戦略の分析
  • 市場参入および市場拡大戦略の分析
  • 市場における「立ち位置」を特定することによる競合戦略

目次

第1章 レポート概要

  • 業界の現状分析と成長ポテンシャルの展望
  • 調査方法とツール
  • 市場内訳
    • セグメント別
    • 地域別

第2章 市場概要と洞察

  • 調査範囲
  • アナリストの洞察と現在の市場動向
    • 主な調査結果
    • 推奨事項
    • 結論

第3章 競合情勢

  • 主要企業分析
  • Celerion
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • Fujirebio Europe NV
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • ICON plc
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • Parexel International Corp.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • 主要戦略分析

第4章 市場セグメンテーション

  • バイオマーカー臨床フェーズアウトソーシングサービスの世界市場：タイプ別
    • 予測バイオマーカー
    • 予後バイオマーカー
    • 安全性バイオマーカー
    • 代替エンドポイント
  • バイオマーカー臨床フェーズアウトソーシングサービスの世界市場：治療領域別
    • 腫瘍学
    • 循環器
    • 神経学
    • 自己免疫疾患
  • バイオマーカー臨床フェーズアウトソーシングサービスの世界市場：エンドユーザー別
    • 製薬会社
    • バイオテクノロジー企業

第5章 地域別分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋
  • 世界のその他の地域

第6章 企業プロファイル

  • Charles River Laboratories International, Inc.
  • Eurofins Scientific corp.
  • GenScript ProBio Biotech Corp.
  • GHO Capital Partners LLP
  • Laboratory Corporation of America（R）Holdings
  • NorthEast BioAnalytical Laboratories LLC
  • Proteome Sciences plc
  • Thermo Fisher Scientific Inc.
  • WuXi AppTec Co., Ltd.
  • Zymewire（Division of Lumerate Inc.）
図表

LIST OF TABLES

  • 1. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 2. GLOBAL PREDICTIVE BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 3. GLOBAL PROGNOSTIC BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL SAFETY BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 5. GLOBAL SURROGATE ENDPOINTS BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 6. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY THERAPEUTIC AREA, 2022-2030 ($ MILLION)
  • 7. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES IN ONCOLOGY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 8. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES IN CARDIOLOGY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 9. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES IN NEUROLOGY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 10. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES IN AUTOIMMUNE DISEASES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 11. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY END-USE, 2022-2030 ($ MILLION)
  • 12. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES FOR PHARMACEUTICAL COMPANIES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 13. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES FOR BIOTECHNOLOGY COMPANIES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 14. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 15. NORTH AMERICAN BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 16. NORTH AMERICAN BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 17. NORTH AMERICAN BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY THERAPEUTIC AREA, 2022-2030 ($ MILLION)
  • 18. NORTH AMERICAN BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY END-USE, 2022-2030 ($ MILLION)
  • 19. EUROPEAN BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 20. EUROPEAN BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 21. EUROPEAN BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY THERAPEUTIC AREA, 2022-2030 ($ MILLION)
  • 22. EUROPEAN BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY END-USE, 2022-2030 ($ MILLION)
  • 23. ASIA-PACIFIC BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 24. ASIA-PACIFIC BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 25. ASIA-PACIFIC BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY THERAPEUTIC AREA, 2022-2030 ($ MILLION)
  • 26. ASIA-PACIFIC BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY END-USE, 2022-2030 ($ MILLION)
  • 27. REST OF THE WORLD BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 28. REST OF THE WORLD BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 29. REST OF THE WORLD BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY THERAPEUTIC AREA, 2022-2030 ($ MILLION)
  • 30. REST OF THE WORLD BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY END-USE, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SHARE BY TYPE, 2022 VS 2030 (%)
  • 2. GLOBAL PREDICTIVE BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SHARE, 2022 VS 2030 (%)
  • 3. GLOBAL PROGNOSTIC BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL SAFETY BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 5. GLOBAL SURROGATE ENDPOINTS BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 6. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SHARE BY THERAPEUTIC AREA, 2022 VS 2030 (%)
  • 7. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES IN ONCOLOGY MARKET SHARE, 2022 VS 2030 (%)
  • 8. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES IN CARDIOLOGY MARKET SHARE, 2022 VS 2030 (%)
  • 9. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES IN NEUROLOGY MARKET SHARE, 2022 VS 2030 (%)
  • 10. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES IN AUTOIMMUNE DISEASES MARKET SHARE, 2022 VS 2030 (%)
  • 11. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY END-USE, 2022 VS 2030 (%)
  • 12. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES FOR PHARMACEUTICAL COMPANIES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 13. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES FOR BIOTECHNOLOGY COMPANIES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 14. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 15. US BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SIZE, 2022-2030 ($ MILLION)
  • 16. CANADA BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SIZE, 2022-2030 ($ MILLION)
  • 17. UK BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SIZE, 2022-2030 ($ MILLION)
  • 18. FRANCE BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SIZE, 2022-2030 ($ MILLION)
  • 19. GERMANY BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SIZE, 2022-2030 ($ MILLION)
  • 20. ITALY BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. SPAIN BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. REST OF EUROPE BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SIZE, 2022-2030 ($ MILLION)
  • 23. INDIA BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. CHINA BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SIZE, 2022-2030 ($ MILLION)
  • 25. JAPAN BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SIZE, 2022-2030 ($ MILLION)
  • 26. SOUTH KOREA BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SIZE, 2022-2030 ($ MILLION)
  • 27. REST OF ASIA-PACIFIC BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SIZE, 2022-2030 ($ MILLION)
  • 28. REST OF THE WORLD BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SIZE, 2022-2030 ($ MILLION)
目次
Product Code: OMR2028015

Global Biomarker Clinical Phase Outsourcing Services Market Size, Share & Trends Analysis Report by Type (Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers, and Surrogate Endpoints), by Therapeutic Area (Oncology, Cardiology, Neurology, and Autoimmune Diseases), and by End-Use (Pharmaceutical Companies and Biotechnology Companies), Forecast Period (2023-2030)

The global biomarker clinical phase outsourcing services market is anticipated to grow at a CAGR of 21.3% during the forecast period (2023-2030). Significant factors including the increasing number of drug development processes, and the rising prevalence of chronic diseases such as cancer, cardiovascular diseases, and neurological disorders has led to an increased focus on biomarkers for early detection, disease monitoring, and treatment response assessment. World Health Organization (WHO) estimated 17.9 million lives every year. Furthermore, according to the American Cancer Society, in 2020, there were an estimated 18.1 million new cancer cases and 9.9 million cancer deaths globally. It is projected that the burden of cancer would increase in coming years as a result of factors including the rising rates of smoking, poor eating habits, and inactivity. Biomarkers indicate a variety of health or disease characteristics.

Segmental Outlook

The global biomarker clinical phase outsourcing services market is segmented on the type, therapeutic area, and end-user. Based on the type, the market is sub-segmented into predictive biomarkers, prognostic biomarkers, safety biomarkers, and surrogate endpoints. Based on the therapeutic area, the market is sub-segmented into oncology, cardiology, neurology, and autoimmune diseases. Further, based on end-user, the market is bifurcated into pharmaceutical companies and biotechnology companies. Among the type, the surrogate endpoints sub-segment is anticipated to hold a considerable share of the market. Surrogate endpoints are a small subset of well-characterized biomarkers with well-evaluated clinical relevance. The segmental growth is attributed to the increasing investment by contract researchers in developing surrogate endpoints for the diagnosis and monitoring of several chronic ailments.

Cardiology Sub-Segment is Anticipated to Hold a Considerable Share of the Global Biomarker Clinical Phase Outsourcing Services Market

Among the therapeutic area, the cardiology sub-segment is expected to hold a considerable share of the global biomarker clinical phase outsourcing services market. The segmental growth is attributed to the increasing prevalence of coronary artery disease, heart failure, valvular heart disease, coupled with the rising demand for coronary artery clinical trials and technical advancement. The British Heart Foundation (BHF) data published in January 2023 reported that in 2021, the most common cardiovascular conditions includes coronary (ischemic) heart disease (global prevalence estimated at 200 million in 2019), peripheral arterial (vascular) disease (110 million), stroke (100 million) and atrial fibrillation (60 million). Additionally, the report revealed that the prevalence of heart and circulatory diseases was 48 million, 100 million, 98 million, 48 million and 340 million in North America, Europe, Africa and the Middle East, Latin America, and Asia & Australia.

Regional Outlook

Global biomarker clinical phase outsourcing services market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, the Asia-Pacific region is anticipated to hold a prominent share of the market around the globe, owing to the increasing prevalence of cancers, increasing number of Western pharmaceutical companies outsourcing their manufacturing activities in emerging economies such as India, and China are driving the biomarker clinical phase outsourcing services market in the Asia Pacific.

The North America Region is Expected to Grow at a Significant CAGR in the Global Biomarker Clinical Phase Outsourcing Services Market

Among all the regions, North America is anticipated to grow at a considerable CAGR over the forecast period. The market growth is attributed to the increasing number of cardiovascular disorders across the North America is estimated to positively impact the clinical trials market growth in upcoming years. According to the American Heart Association (AHA), CVDs remains as the leading cause of death in the US, accounted for 928,741 deaths in the year 2020. American Cancer Society, estimated in 2023, over 1.9 million new cancer cases are expected to be diagnosed in the US. Approximately 609,820 deaths from cancer are expected in the US in 2023, which is about 1,670 deaths per day. Additionally, owing to the presence of established contract research organizations specializing in biomarker clinical phase outsourcing services, such as global clinical trials, Caidya, ICON plc, and several others. Owing to the introduction of several innovative, ground-breaking technologies in clinical research and the provision of state-of-the-art infrastructure, numerous clinical trials for heart disorders are being performed across the region. As per Clinicaltrials.gov, as of September 2023, around 5,068 enduring biomarker clinical phase outsourcing services are registered in the US.

Market Players Outlook

The major companies serving the global biomarker clinical phase outsourcing services market include Celerion, Fujirebio Europe NV, ICON plc, and Parexel International Corp., among others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in March 2023, healthcare technology firm Koneksa Health Inc., expanded collaboration with life sciences consulting firm SSI Strategy to scale evidence-based digital biomarker adoption in clinical trials. The digital biomarker solutions of Koneksa include a platform which allows research sponsors and clinical sites to impeccably aggregate data, in real-time, from patient diaries, devices, ePROs, and clinical assessments, to deliver a complete view of a person's health.

The Report Covers

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global biomarker clinical phase outsourcing services market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. Celerion
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Fujirebio Europe NV
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. ICON plc
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Parexel International Corp.
    • 3.5.1. Overview
    • 3.5.2. Financial Analysis
    • 3.5.3. SWOT Analysis
    • 3.5.4. Recent Developments
  • 3.6. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Biomarker Clinical Phase Outsourcing Services Market by Type
    • 4.1.1. Predictive Biomarkers
    • 4.1.2. Prognostic Biomarkers
    • 4.1.3. Safety Biomarkers
    • 4.1.4. Surrogate Endpoints
  • 4.2. Global Biomarker Clinical Phase Outsourcing Services Market by Therapeutic Area
    • 4.2.1. Oncology
    • 4.2.2. Cardiology
    • 4.2.3. Neurology
    • 4.2.4. Autoimmune Diseases
  • 4.3. Global Biomarker Clinical Phase Outsourcing Services Market by End-Use
    • 4.3.1. Pharmaceutical Companies
    • 4.3.2. Biotechnology Companies

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Charles River Laboratories International, Inc.
  • 6.2. Eurofins Scientific corp.
  • 6.3. GenScript ProBio Biotech Corp.
  • 6.4. GHO Capital Partners LLP
  • 6.5. Laboratory Corporation of America® Holdings
  • 6.6. NorthEast BioAnalytical Laboratories LLC
  • 6.7. Proteome Sciences plc
  • 6.8. Thermo Fisher Scientific Inc.
  • 6.9. WuXi AppTec Co., Ltd.
  • 6.10. Zymewire (Division of Lumerate Inc.)